28 April, Boston—Molecular testing is transforming post-transplant care, reducing the need for invasive biopsies and personalizing medication regimens to lower the risk of infection and other downstream side effects, according to a presentation by Jeffrey Teuteberg, MD, this morning at the Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT)
“We’ve had a bit of a cookie-cutter approach to post-operative care, managing heart transplant patients in roughly the same way,” said Dr. Teuteberg, Associate Chief of Cardiology and Section Chief of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support at Stanford Medicine. “Besides addressing issues that come up for a specific individual, there hasn’t been a lot of personalization.”
Post-transplant surveillance has traditionally included frequent biopsies of heart tissue and blood tests for the first few years following the transplant when the risk of organ rejection and infection is highest.
“Patients hate having the biopsies, but we haven’t had a good, non-invasive alternative,” Dr. Teuteberg said.
An early molecular test, gene expression profiling, made inroads by distinguishing between low- and high-risk transplant patients. Now, cell-free DNA (cf-DNA) testing, which identifies small DNA fragments in the bloodstream from a donor’s heart, can detect potential heart injury or rejection as early as a few weeks post-transplant.
“When we started using cell-free DNA testing as early as a month post-transplant, we eliminated 95 percent of the biopsies during the first few years,” he said.
Using cell-free DNA testing to monitor patient response holds the promise of enabling physicians to reduce the dosage of immunosuppressive medicines and steroids in low-risk patients.
“Post-transplant medications keep the body from rejecting the donor heart, but they also can have deleterious health effects, including infections, impaired kidney function, and an increased risk for cancer,” he said. “Being able to decrease the dosage may benefit patients by reducing the incidence or severity of these complications.”
Molecular testing also offers the potential to:
screen patients for viruses to personalize the duration of post-transplant
antivirals and antibiotics
test the patients’ own DNA to determine levels of viruses and bacteria in the gut biome, which may correlate with their level of immunosuppression
detect early cancer cells to adjust screening rates for patients at high risk
study gene expression in the heart tissue removed during biopsies.
Dr. Teuteberg said molecular testing is already improving access to heart transplants and quality of life for recipients.
“One of the things that disadvantages patients who need a transplant is their ability to get to a transplant center, not only for the procedure but for ongoing testing,” he said. “Being able to surveil patients remotely is more convenient for patients. I think it democratizes the heart transplant in a way that is really exciting.”
While it’s difficult to quantify, Dr. Teuteberg said better surveillance of patients over a longer period of time could impact survival and outcome rates for heart transplant recipients.
“Even if the impact is relatively modest, it would be a huge change because we haven’t really been able to bend the survival curve beyond the first six months or a year despite all the great advances of the past 20 years,” he said. “If we’re better at identifying who’s at high risk of rejection and preventing that, it will have a huge tail in terms of the benefit over time.
“It doesn’t take much of a change of the survival curve early post-transplant to have an impact on long-term survival,” Dr. Teuteberg said.
END
About ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support, and innovative therapies via research, education, and advocacy. ISHLT members focus on transplantation and a range of interventions and therapies related to advanced heart and lung disease.
The ISHLT Annual Meeting and Scientific Sessions will be held from 27-30 April at the John B. Hynes Veterans Memorial Convention Center in Boston.
Contact:
Jess Burke, Director of Marketing and Communications
+1.312.224.0015
[email protected]
Media Contact
Jessica Burke
International Society for Heart and Lung Transplantation
Office: 3122240015
Keywords
/Health and medicine/Clinical medicine/Medical diagnosis/Biomarkers
/Health and medicine/Human health/Public health/Organ donation
/Health and medicine/Clinical medicine/Medical treatments/Transplantation/Tissue transplantation
/Health and medicine/Clinical medicine/Medical diagnosis/Medical tests/Biopsies
/Health and medicine/Clinical medicine/Medical treatments/Transplantation
bu içeriği en az 2000 kelime olacak şekilde ve alt başlıklar ve madde içermiyecek şekilde ünlü bir science magazine için İngilizce olarak yeniden yaz. Teknik açıklamalar içersin ve viral olacak şekilde İngilizce yaz. Haber dışında başka bir şey içermesin. Haber içerisinde en az 12 paragraf ve her bir paragrafta da en az 50 kelime olsun. Cevapta sadece haber olsun. Ayrıca haberi yazdıktan sonra içerikten yararlanarak aşağıdaki başlıkların bilgisi var ise haberin altında doldur. Eğer yoksa bilgisi ilgili kısmı yazma.:
Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:
Keywords
Tags: advancements in heart transplant surveillancecell-free DNA testing in organ transplantationgene expression profiling in post-transplant careheart transplant recipient management strategiesimpact of molecular tests on transplant outcomesinnovations in heart transplant monitoring techniquesmolecular testing in heart transplant carenon-invasive alternatives to heart biopsiespersonalized medication regimens for transplant patientspersonalized monitoring for heart transplant recipientsreducing infection risk in heart transplant patientsrole of genetics in post-operative heart care
